Vabicaserin hydrochloride (Standard)

[1]. Chen W. Repeated administration of 5‐hydroxytryptamine 2C agonist MK212 produces a sensitization effect of antipsychotic activity. IUBMB life. 2016 Dec;68(12):985-93. [Content Brief]

[2]. Neelamegam R, et al. Imaging evaluation of 5HT2C agonists, [(11)C]WAY-163909 and [(11)C]vabicaserin, formed by Pictet-Spengler cyclization. Journal of medicinal chemistry. 2014 Feb 27;57(4):1488-94.

[3]. Ding N, et al. The enhancing effect of 5-HT on phasic contractions of human isolated distal ureter and the mechanisms mediating these effects. European journal of pharmacology. 2023 Jun 15;949:175715.

[4]. Shen JH, et al. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. J Psychiatr Res. 2014 Jun;53:14-22.

[5]. Teixeira-Castro A, et al. Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain : a journal of neurology. 2015 Nov;138(Pt 11):3221-37.

[6]. Dunlop J, et al. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. The Journal of pharmacology and experimental therapeutics. 2011 Jun;337(3):673-80. [Content Brief]

[7]. Rosenzweig-Lipson, et al. 5-HT₂C Agonists as Therapeutics for the Treatment of Schizophrenia. Novel Antischizophrenia Treatments, edited by M. A. Geyer and G. Gross, vol. 213, Springer, 2012, pp. 147–165.

[8]. Ogino S, et al. Systemic administration of 5-HT(2C) receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model. Pharmacol Biochem Behav. 2013 Jul;108:8-15.